[Management of erectile dysfunction in the cardiac patient].
Gratzke
C
C
Urologische Klinik und Poliklinik der LMU München. Christian.Gratzke@med.uni-muenchen.de
Becker
A J
AJ
Park
J-W
JW
Reich
O
O
Waldkirch
E
E
Schlenker
B
B
Stief
C G
CG
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002423:Cause of Death; D003327:Coronary Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004734:Energy Metabolism / Q000502:physiology; D006801:Humans; D018783:Impotence, Vasculogenic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D010353:Patient Education as Topic; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects; D010808:Physical Examination; D012307:Risk Factors
D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human